Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery

Diabetes

Volumn 67, Issue 2, 2018, Pages 309-320

  Briere, Daniel A ^a   Bueno, Ana B ^b   Gunn, Ellen J ^c   Michael, M Dodson ^a   Sloop, Kyle W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AND COMPANY   (Spain)

^c Advanced Testing Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; EXENDIN 4; G PROTEIN COUPLED RECEPTOR 40; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; RECEPTOR; SITAGLIPTIN; SOMATOSTATIN RECEPTOR 5 ANTAGONIST; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV INHIBITOR; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GPBAR1 PROTEIN, MOUSE; GPR40 PROTEIN, MOUSE; HORMONE RECEPTOR; NEW DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; COMBINATION DRUG THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; HYPERGLYCEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DRUG DESIGN; DRUG RESISTANCE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MUTANT MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRECLINICAL STUDY; PROOF OF CONCEPT;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; GLUCAGON-LIKE PEPTIDE 1; HYPERGLYCEMIA; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MODELS, BIOLOGICAL; PROOF OF CONCEPT STUDY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; SITAGLIPTIN PHOSPHATE;

EID: 85041224883     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db17-0607     Document Type: Conference Paper

References (50)

1. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010;252: 966–971
2. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013;36: 2175–2182
3. Vidal J, de Hollanda A, Jiménez A. GLP-1 is not the key mediator of the health benefits of metabolic surgery. Surg Obes Relat Dis 2016;12:1225–1229
4. Holst JJ, Madsbad S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis 2016;12:1236–1242
5. Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005;48:2236–2240
6. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3:597–601
7. Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007;92:4678–4685
8. Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012;22:1084–1096
9. Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60: 2308–2314
10. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al. Exaggerated glucagon-like peptide 1 response is important for improved b-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013;62: 3044–3052
11. Garibay D, McGavigan AK, Lee SA, et al. b-Cell glucagon-like peptide-1 receptor contributes to improved glucose tolerance after vertical sleeve gastrectomy. Endocrinology 2016;157:3405–3409
12. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612–4619
13. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008;5:73–94
14. Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005;27:210–215
15. Kothare PA, Linnebjerg H, Isaka Y, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 2008;48:1389–1399
16. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11–22
17. Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 2011;141:950–958
18. Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250:234–241
19. Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg 2014;24:241–252
20. Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015;6:3–18
21. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab 2017;19:336–347
22. Kassem MA, Durda MA, Stoicea N, Cavus O, Sahin L, Rogers B. The impact of bariatric surgery on type 2 diabetes mellitus and the management of hypoglycemic events. Front Endocrinol (Lausanne) 2017;8:37
23. Gletsu-Miller N, Wright BN. Mineral malnutrition following bariatric surgery. Adv Nutr 2013;4:506–517
24. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141–151
25. Duffy JL, Bao J, Ondeyka DL, et al. Preparation of substituted spirocyclic amine, particularly spiroxazolidinone compounds, as SSTR5 antagonists. US patent US8742110 BB. 3 June 2014
26. Briere DA, Ruan X, Cheng CC, et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS One 2015;10:e0136873
27. Du X, Dransfield PJ, Lin DCH, et al. Improving the pharmacokinetics of GPR40/ FFA1 full agonists. ACS Med Chem Lett 2014;5:384–389
28. Patterson JT, Ottaway N, Gelfanov VM, et al. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem Biol 2011;6:135–145
29. Jun LS, Showalter AD, Ali N, et al. A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS One 2014;9:e93746
30. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:14843–14847
31. Campbell JE, Ussher JR, Mulvihill EE, et al. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med 2016;22:84–90
32. Pamir N, Lynn FC, Buchan AM, et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab 2003;284:E931–E939
33. Teng M, Johnson MD, Thomas C, et al. Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 2007;17:5472–5478
34. Pais R, Gribble FM, Reimann F. Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab 2016;7:24–42
35. Martin PA, Faulkner A. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep. J Endocrinol 1996;151:107–112
36. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000;278:E1010–E1018
37. Chisholm C, Greenberg GR. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am J Physiol Endocrinol Metab 2002;283:E311–E317
38. Farb TB, Adeva M, Beauchamp TJ, et al. Regulation of endogenous (male) rodent GLP-1 secretion and human islet insulin secretion by antagonism of somatostatin receptor 5. Endocrinology 2017;158:3859–3873
39. Gorski JN, Pachanski MJ, Mane J, et al. GPR40 reduces food intake and body weight through GLP-1. Am J Physiol Endocrinol Metab 2017;313:E37–E47
40. Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011;25:1066–1071
41. Hauge M, Vestmar MA, Husted AS, et al. GPR40 (FFAR1) - combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab 2014;4:3–14
42. Bock G, Dalla Man C, Micheletto F, et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010;73: 189–196
43. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002;172:355–362
44. le Roux CWWR, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246: 780–785
45. Pucci A, Cheung WH, Jones J, et al. A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy. Endocrinol Diabetes Metab Case Rep 2015;2015:150020
46. Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003;88:4897–4903
47. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210–215
48. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008;247:401–407
49. Näslund E, Grybäck P, Hellström PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997;21:387–392
50. Dar MS, Chapman WH 3rd, Pender JR, et al. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg 2012;22: 1077–1083